Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
A precision cancer treatment that targets rare genetic mutations that exist in about 5,000 people in the U.S. instead of the tumor's location in the body has shown success in three-quarters of patients, researchers said Wednesday.The 55 patients ranged in age from 4 months to 76 years, and entered the trial from 2015 to 2017 .TRK fusions are found in a range of cancer types but tend to be unusual in common cancers, occurring in between 0.2 percent and 3 percent of cases. However, in some rare cancers, the fusions are present in nearly every case, researchers say.
FOLLOW THIS ARTICLE